The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of an MVA vaccine targeting p53 in cancer.
Vincent M. Chung
Research Funding - Novartis
Nicola Hardwick
No relevant relationships to disclose
Joshua D.I. Ellenhorn
No relevant relationships to disclose
Jonathan R. Espenschied
No relevant relationships to disclose
Dean Lim
No relevant relationships to disclose
Peiguo Chu
No relevant relationships to disclose
Dajun Qian
No relevant relationships to disclose
Joseph Kim
No relevant relationships to disclose
Joseph Chao
Research Funding - Cerulean Pharma
Marwan Fakih
No relevant relationships to disclose
Yun Yen
No relevant relationships to disclose
Don J. Diamond
No relevant relationships to disclose